TWM393167U - Multi-coating macro-granule structure comprising probiotics - Google Patents
Multi-coating macro-granule structure comprising probiotics Download PDFInfo
- Publication number
- TWM393167U TWM393167U TW099203609U TW99203609U TWM393167U TW M393167 U TWM393167 U TW M393167U TW 099203609 U TW099203609 U TW 099203609U TW 99203609 U TW99203609 U TW 99203609U TW M393167 U TWM393167 U TW M393167U
- Authority
- TW
- Taiwan
- Prior art keywords
- probiotics
- layer
- probiotic
- layered
- core
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 53
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 53
- 239000004515 macrogranule Substances 0.000 title abstract description 6
- 239000011248 coating agent Substances 0.000 title abstract 2
- 238000000576 coating method Methods 0.000 title abstract 2
- 239000010410 layer Substances 0.000 claims abstract description 33
- 230000000529 probiotic effect Effects 0.000 claims abstract description 23
- 239000011241 protective layer Substances 0.000 claims abstract description 12
- 239000002245 particle Substances 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000011859 microparticle Substances 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 229920001800 Shellac Polymers 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 239000004208 shellac Substances 0.000 claims description 6
- 235000013874 shellac Nutrition 0.000 claims description 6
- 229940113147 shellac Drugs 0.000 claims description 6
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
- 229920002494 Zein Polymers 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 239000005019 zein Substances 0.000 claims description 4
- 229940093612 zein Drugs 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 240000008397 Ganoderma lucidum Species 0.000 claims description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims 1
- 241000195628 Chlorophyta Species 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 235000020712 soy bean extract Nutrition 0.000 claims 1
- 239000002346 layers by function Substances 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 239000002253 acid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 238000010306 acid treatment Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
M393167 五、新型說明: 【新型所屬之技術領域】 本創作是有關於一種多層微粒結構, 一種具有益生菌之多層微粒結構。 、別疋有關於 【先前技術】 目前,市面上常見的益生菌產品,根 ^寅化過程,依序分為以下四種類型:粉末;;^里技術 包埋型益生菌、晶球益生菌、雙層微包埋型:土囷、巨 末益生菌係指未經包埋處理的益生菌,1=^。粉 :::耐久存,其菌體易被破壞。而巨包埋型益生:耐 硬膠囊包埋益生菌’雖可保護菌體 二 ΐ 易使釋出菌體的時機不ί 包:材料再以微膠囊包埋益生菌,其雖:為 ^ 能溶解釋出,且其價格昂 層微包埋型益生菌,係指於益生菌表面包覆一; ^貝,以隔離菌體與外界空氣、減接觸,並保存^ 體之活性,接著於外料包覆—層特殊_, 埋可使菌體耐胃酸、总、、六站 ._ θ已 產商因尚未建立此包於國内各益生菌相關 膠囊仍須仰賴進生菌粉末顆粒或 — 代理商導致國内自產益生菌相關產 "Γ八女疋不足,導致儲存期短、活菌數降低等缺點。 故益生菌體安定性不^,儲存期短、活菌數降低、加強 M393167 抵抗力及提升勝道中溶解能力係為待將日解決之 【新型内容】 θ有鑑於上述習知技藝之問題,本創作之目的就是在 提供-種具有益生紅乡層聽結構,續決益生菌安 定性:足、儲存期短、活菌數降低之問題、並加強菌體 抵抗月酸及腸道轉能力’使菌體更為敎,並且能 升我國相關產業於國際之競爭力。 根據本創作之目的’提出—種具有益生菌之多層微 粒結構,其結構由内而外依序包含有一核心、一益生菌 層、-營養機能層及-保護層。其中該益生菌層;包覆 於該核心外’且該營養機能層係包覆於該益生菌層外, 而該保護層係再包覆於該營養機能層外。 承上所述,因依本創作之具有益生菌之多層微粒結 構,其可具有一或多個下述優點: ⑴此具益生菌之多層微粒結構係含有保護層,因 此可解決於胃酸環境被破壞的問題,另於驗性腸道環境 中較易溶解釋出。 (2)此具益生菌之多層微粒結構具係含有營養機能 層’因此不僅可供益生菌營養物f,更可使人體食入後 保健康及青春。 5 M393167 (3) 此益生菌之多層微粒結構具有益生菌層,因此 可調整體質、維持消化道機能及改變腸道菌相。 (4) 此益生菌之多層微粒結構,可增加該菌體二次 加工之稳定性及其儲存安定性。 【實施方式】 以下將參照相關圖式’說明依本創作之具有益生菌 之多層微粒結構組成之實施例,為使便於理解,下述實 施例中之相同元件係以相同之符號標示來說明。 請參閱第1圖’其係為本創作之具有益生菌之多詹 微粒結構組成之示意圖。圖中,益生菌之多層微粒結構 由内而外依序包含有核心1、益生菌層2、營養機能層3 及保護層4,其中,益生菌層2係包覆於核心1外,且 營養機能層3係包覆於益生菌層2表面,此外,保護層 4係再包覆於營養機能層3外。其中,核心1係為碳水 化合物,其包含蔗糖、葡萄糖或果糖,益生菌層2係包 含LGG (L. rhamnosus GG)乳酸菌、乾酪乳酸菌 (Lactobacillus paracasei)、比菲德龍根菌(Bifidobacterium longum)或比菲德氏菌(Bifidobacterium bifidum),而營養 機能層3係包含膠原蛋白、靈芝萃取物、果寡糖、菊糖、 大立萃取物或缓甲基纖維素(carboxymethyl cellulose)、 綠藻多糖、玻尿酸、葡萄糖胺、超氧歧化酶(superoxide dismutase,SOD)或褐澡多醣,另外,保護層係為腸溶性 膜衣素材,其包含蟲膠(shellac)、羥丙基甲基纖維素 (hydroxypropyl methylcellulose phthalate,HPMCP)、玉米 M393167 蛋白(zein)、明膠、阿拉伯膠、膠原蛋白或海藻酸鈉。 實施例二:本創作之較佳實施例 糖為核包埋之微珠立· 以糖蕊為核心包埋之微粒之材料係包含糖蕊、 ⑽GG)乳酸菌 '膠原蛋白及靈芝萃取物及腸 溶性膜衣素材。 溶性評估試驗: • 取1〇 S樣品加入90 mL Mcilvaine的緩衝液(pH 6 8M393167 V. New description: [New technical field] This creation is about a multi-layered particle structure, a multi-layered particle structure with probiotics. Do not know about [previous technology] At present, the common probiotic products on the market, the roots and sputum process, are divided into the following four types: powder;; ^ technology embedded type probiotics, crystal ball probiotics Double-layer micro-embedded type: soil mites, giant end probiotics refers to probiotics that have not been embedded, 1=^. Powder ::: Durable, its bacteria are easily destroyed. The giant-embedded probiotics: hard-encapsulated probiotics can protect the bacteria from the bacteria. The timing of releasing the bacteria is not good. Package: The material is then encapsulated with probiotics in microcapsules. Dissolved, and its price is high-layer micro-embedded probiotics, which refers to the surface of probiotics coated with one; ^ shell, to isolate the bacteria from the outside air, reduce contact, and preserve the activity of the body, followed by Material coating - layer special _, burying bacteria can be resistant to stomach acid, total, six stations. _ θ has been established because the package has not yet established this package in the domestic probiotics related capsules still have to rely on the powder particles or - Agents lead to the domestic production of probiotics-related products, "the lack of Γ eight female 疋, resulting in short storage period, reduced viable counts and other shortcomings. Therefore, the stability of probiotic cells is not good, the storage period is short, the number of viable bacteria is reduced, the resistance of M393167 is strengthened, and the solvency in the Shengdao is improved. The new content is solved θ in view of the above-mentioned problems of the prior art, The purpose of the creation is to provide a structure with probiotics and red soil layers, to maintain the stability of probiotics: the problem of short foot, short storage period, and reduced viable count, and to strengthen the ability of bacteria to resist acid and intestinal transit. The bacteria are more awkward and can enhance the competitiveness of our related industries in the world. According to the purpose of the present invention, a multi-layered microparticle structure having probiotics is provided, the structure comprising a core, a probiotic layer, a nutrient function layer and a protective layer in sequence from the inside to the outside. Wherein the probiotic layer; coated on the outer core' and the nutrient function layer is coated outside the probiotic layer, and the protective layer is re-coated outside the nutrient function layer. According to the above, the multi-layered microparticle structure with probiotics can have one or more of the following advantages: (1) The multi-layered microparticle structure with probiotics contains a protective layer, so that it can be solved in the stomach acid environment. The problem of destruction is explained by the more soluble in the intestinal environment. (2) The multi-layered micro-structure of the probiotics contains a nutrient function layer. Therefore, not only can the probiotics nutrient f be provided, but also the human body can be healthy and youthful after being ingested. 5 M393167 (3) The multi-layered micro-particle structure of this probiotic has a probiotic layer, so the whole body quality can be adjusted, the function of the digestive tract can be maintained and the intestinal flora can be changed. (4) The multi-layered particle structure of the probiotic can increase the stability of the secondary processing of the cell and its storage stability. [Embodiment] Hereinafter, embodiments of the multi-layered particle structure having probiotics according to the present invention will be described with reference to the related drawings. For the sake of easy understanding, the same elements in the following embodiments are denoted by the same reference numerals. Please refer to Figure 1 for a schematic diagram of the composition of the multi-Zhan particle structure with probiotics. In the figure, the multi-layered microparticle structure of the probiotic comprises the core 1, the probiotic layer 2, the nutrient function layer 3 and the protective layer 4 from the inside to the outside, wherein the probiotic layer 2 is coated on the core 1 and is nutritious. The functional layer 3 is coated on the surface of the probiotic layer 2, and the protective layer 4 is further coated on the outside of the nutrient function layer 3. Among them, the core 1 is a carbohydrate containing sucrose, glucose or fructose, and the probiotic layer 2 comprises LGG (L. rhamnosus GG) lactic acid bacteria, Lactobacillus paracasei, Bifidobacterium longum or Bifidobacterium bifidum, and the nutrient function layer 3 contains collagen, Ganoderma lucidum extract, fructooligosaccharide, inulin, Dali extract or carboxymethyl cellulose, chlorella, Hyaluronic acid, glucosamine, superoxide dismutase (SOD) or brown bath polysaccharide, in addition, the protective layer is an enteric film material containing shellac, hydroxypropyl methylcellulose Phthalate, HPMCP), corn M393167 protein (zein), gelatin, acacia, collagen or sodium alginate. Example 2: The preferred embodiment of the present invention is a micro-bead of the core-embedded microparticles. The material of the microparticles embedded in the core of the sugar core comprises a sugar core, (10) GG) lactic acid bacteria 'collagen and extracts of ganoderma lucidum and enteric properties. Membrane material. Solubility assessment test: • Take 1 〇 S sample into 90 mL Mcilvaine buffer (pH 6 8
Mcilvaine’ s Buffer),再利用磁石以80 rpm轉速緩慢攪 拌至完全崩解並紀錄崩解所需時間,結果如表丨所示, 其中以玉米蛋白為腸溶性膜衣素材之微粒In granule III),及以10%蟲膠為腸溶性膜衣素材之微粒% (Macro-granule VI)及微粒 VII (Macro-granule VII) ’ 其崩解時門 皆為60分鐘,另以10%蟲膠為腸溶性膜衣素材之微粒 (Macro-granule IV)及以2%蟲膠為腸溶性膜衣素材之微粒γ φ (Macro-granule V) ’其崩解時間皆為30分鐘,以上崩解時間為兴 - 生菌於腸道釋放之適當時機,此結果亦顯示玉米蛋白及息膠係適 為較佳之腸溶性膜衣素材。 ~ 7 M393167 表1:包埋微粒崩解(溶解性)試驗 樣品 崩解時間 微粒III 60分鐘内 微粒IV 30分鐘内 微粒V 30分鐘内 微粒VI 60分鐘内 微粒VII 60分鐘内 原始乳酸菌粉末 1分鐘内 耐酸性評估試驗: 耐酸性評估試驗又分為,不經酸處理及酸處理試 驗。不經酸處理係指取1 g樣品加入100 mL Mcilvaine的 緩衝液(pH 6.8 Mcilvaine’s Buffer),再利用磁石以 80 rpm 缓慢攪拌至完全崩解,經適當稀釋後,以傾注平板法計 數存活的菌數。另外,酸處理試驗係指取1 g樣品於100 mL 填酸鹽緩衝液(phosphate buffered saline,PBS, pHl .5)中,再以50 rpm轉速震盪1小時,並以12,000 rpm 轉速高速離心15分鐘,爾後去除上層之模擬胃液,再將 下層的沉澱物加入100 mL模擬腸液並使懸浮,接著以 80 rpm轉速震盪,經適當稀釋後,以傾注平板法計數存 活的菌數並計算存活率,而其存活率算法係為不經酸處 理之菌數/經酸處理之菌數xlOO%。實驗結果如表2所 示,其中以糖蕊為核心並以10%蟲膠為腸溶性膜衣之 M393167 GM VI及GM VII之存活率較高(85.17%及80.24%),亦可知 10%蟲膠於此係適為耐酸之腸溶性膜衣素材。 表2包埋微粒耐酸試驗 項目 樣品 不經酸處理 之細胞數目 經酸處理之 細胞數目 存活率(%) 微粒III 1.24Χ10,υ 5.32X10, 0.43 微粒IV 1.13X10" 3.96Χ108 0.35 微粒V 2.25Χ10ιυ 8.39Χ108 3.73 微粒VI 1.73X10y 1.51X10y 85.17 微粒VII 5.77Χ10ιυ 4.63ΧΚΓ 80.24 原始乳酸菌粉末 2.21Χ1011 6.65X10" 0.003 水分含量分析: 取3g樣品裝於樣品皿中,打開蓋子後放置於105°C φ 烘箱中烘乾4小時,使微粒之水分蒸散,在烘箱中將蓋 . 子蓋上再取出培養皿,將培養皿置於密閉容器中並於容 器中加入乾燥劑,待微粒溫度與室溫平衡後取出秤重, 再放置於105°C烘箱中烘乾1小時,置於密閉容器中回 溫後取出秤重,反覆進行以上步驟至重量不再改變止, 並依下列公式計算水分含量,其結果顯示,所有微粒之 水含量皆係於8%以下,亦顯示可改善產品不耐儲存之 問題。 9 M393167 水分含量=乾燥前重一乾燥後重 X 100% 乾燥前重 水活性分析: 取2g微粒置於樣品盒中,以 其結果顯示水活性皆於0.7以下, 菌腐敗之問題。 以水活性分析儀分析之, ‘’亦表示可改善細菌或黴 以上所述僅為舉例性,而非為限制性者。任何未脫 離本創作之精神與範疇,而對其進行之等效修改或變 更,均應包含於後附之申請專利範圍中。 【圖式簡單說明】 第1圖係為本創作之具有益生菌之多層微粒結構組成 之示意圖。 【主要元件符號說明】 1 :核心; 2 : M yJ. ±i 益生菌層; 營養機能層;以及 保護層。 4Mcilvaine's Buffer), the magnet was slowly stirred at 80 rpm until it completely disintegrated and the time required for disintegration was recorded. The results are shown in the table, in which zein is an enteric film material Particle In granule III) And 10% shellac is the enteric film material% (Macro-granule VI) and microparticle VII (Macro-granule VII) 'when it disintegrates, the door is 60 minutes, and 10% shellac is the intestine. The particles of the soluble film material (Macro-granule IV) and the particles γ φ (Macro-granule V) with 2% shellac as the enteric film material have a disintegration time of 30 minutes, and the above disintegration time is good. - Appropriate timing of bacterial release in the intestine. This result also shows that zein and gelatin are suitable as enteric film materials. ~ 7 M393167 Table 1: Embedding microparticles disintegration (solubility) Test sample Disintegration time Particles III Within 60 minutes Microparticles IV Within 30 minutes Particles V Within 30 minutes Particles VI Within 60 minutes Particles VII Within 1 minute of original lactic acid bacteria powder 1 minute Internal acid resistance evaluation test: The acid resistance evaluation test is further divided into no acid treatment and acid treatment test. Without acid treatment, 1 g of sample was added to 100 mL of Mcilvaine's buffer (pH 6.8 Mcilvaine's Buffer), and the magnet was slowly stirred at 80 rpm until completely disintegrated. After appropriate dilution, the surviving bacteria were counted by pouring plate method. number. In addition, the acid treatment test refers to taking 1 g of sample in 100 mL of phosphate buffered saline (PBS, pH 1.5), shaking at 50 rpm for 1 hour, and centrifuging at 12,000 rpm for 15 minutes. Then, the upper simulated gastric juice is removed, and the lower layer of the precipitate is added to 100 mL of simulated intestinal juice and suspended, followed by shaking at 80 rpm. After appropriate dilution, the number of surviving bacteria is counted by a pour plate method and the survival rate is calculated. The survival rate algorithm is the number of bacteria without acid treatment / the number of bacteria treated by acid x lOO%. The experimental results are shown in Table 2. Among them, the survival rate of M393167 GM VI and GM VII with sugar core as the core and 10% shellac as the enteric film is higher (85.17% and 80.24%), and 10% insects are also known. The glue is suitable for acid-resistant enteric film material. Table 2 Embedding microparticles acid-resistant test item Samples without acid treatment Number of cells treated with acid-treated cell survival rate (%) Particles III 1.24Χ10, υ 5.32X10, 0.43 Particles IV 1.13X10" 3.96Χ108 0.35 Particles V 2.25Χ10ιυ 8.39 Χ108 3.73 Particle VI 1.73X10y 1.51X10y 85.17 Particle VII 5.77Χ10ιυ 4.63ΧΚΓ 80.24 Original lactic acid bacteria powder 2.21Χ1011 6.65X10" 0.003 Moisture content analysis: Take 3g sample in sample dish, open the lid and place it in 105°C φ oven After drying for 4 hours, the water of the microparticles is evaporated. The lid is placed in an oven and the petri dish is taken out. The culture dish is placed in a closed container and a desiccant is added to the container. After the temperature of the particles is balanced with the room temperature, the scale is taken out. Heavy, and then placed in an oven at 105 ° C for 1 hour, placed in a closed container and then warmed up, take out the weight, repeat the above steps until the weight is no longer changed, and calculate the moisture content according to the following formula, the results show that The water content of all the particles is below 8%, which also shows that the product is not resistant to storage. 9 M393167 Moisture content = heavy before drying, dry weight X 100% Heavy before drying Water activity analysis: Take 2g of microparticles in the sample box, and the results show that the water activity is below 0.7, the problem of bacterial spoilage. As analyzed by the water activity analyzer, '' also means that the bacteria or mold can be improved. The above is merely illustrative and not limiting. Any changes or modifications that are made without departing from the spirit and scope of this creation shall be included in the scope of the appended patent application. [Simple description of the diagram] Figure 1 is a schematic diagram of the composition of the multi-layered microparticles with probiotics. [Main component symbol description] 1 : Core; 2 : M yJ. ±i Probiotic layer; Nutritional function layer; and Protective layer. 4
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099203609U TWM393167U (en) | 2010-02-26 | 2010-02-26 | Multi-coating macro-granule structure comprising probiotics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099203609U TWM393167U (en) | 2010-02-26 | 2010-02-26 | Multi-coating macro-granule structure comprising probiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWM393167U true TWM393167U (en) | 2010-12-01 |
Family
ID=45082005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW099203609U TWM393167U (en) | 2010-02-26 | 2010-02-26 | Multi-coating macro-granule structure comprising probiotics |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWM393167U (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113040270A (en) * | 2021-04-29 | 2021-06-29 | 西南科技大学 | Preparation method of microecological preparation for pigs |
| CN113133505A (en) * | 2021-06-01 | 2021-07-20 | 西南科技大学 | Preparation method of micro-ecological compound preparation containing clostridium butyricum |
| CN113940395A (en) * | 2021-11-17 | 2022-01-18 | 西南科技大学 | A kind of preparation method of probiotics preparation for piglets |
| CN114223795A (en) * | 2021-12-21 | 2022-03-25 | 西南科技大学 | Preparation method of probiotic feed for piglets |
| CN116250631A (en) * | 2023-02-10 | 2023-06-13 | 杭州百芮生物科技有限公司 | Embedding structure of probiotics and preparation method thereof |
| CN117918529A (en) * | 2023-12-28 | 2024-04-26 | 青岛蔚蓝生物集团有限公司 | Probiotic crystal ball containing lactobacillus plantarum and preparation method thereof |
-
2010
- 2010-02-26 TW TW099203609U patent/TWM393167U/en not_active IP Right Cessation
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113040270A (en) * | 2021-04-29 | 2021-06-29 | 西南科技大学 | Preparation method of microecological preparation for pigs |
| CN114886010A (en) * | 2021-04-29 | 2022-08-12 | 西南科技大学 | Preparation method of microecological preparation for pigs |
| CN114886010B (en) * | 2021-04-29 | 2023-05-23 | 西南科技大学 | A kind of preparation method of microecological preparation for pigs |
| CN113133505A (en) * | 2021-06-01 | 2021-07-20 | 西南科技大学 | Preparation method of micro-ecological compound preparation containing clostridium butyricum |
| CN114668081A (en) * | 2021-06-01 | 2022-06-28 | 西南科技大学 | Preparation method of micro-ecological compound preparation containing clostridium butyricum |
| CN114668081B (en) * | 2021-06-01 | 2023-05-23 | 西南科技大学 | A kind of preparation method of microecological compound preparation containing Clostridium butyricum |
| CN113940395B (en) * | 2021-11-17 | 2023-05-23 | 西南科技大学 | Preparation method of probiotic preparation for piglets |
| CN113940395A (en) * | 2021-11-17 | 2022-01-18 | 西南科技大学 | A kind of preparation method of probiotics preparation for piglets |
| CN114223795A (en) * | 2021-12-21 | 2022-03-25 | 西南科技大学 | Preparation method of probiotic feed for piglets |
| CN114223795B (en) * | 2021-12-21 | 2023-05-23 | 西南科技大学 | Preparation method of probiotics feed for piglets |
| CN116250631A (en) * | 2023-02-10 | 2023-06-13 | 杭州百芮生物科技有限公司 | Embedding structure of probiotics and preparation method thereof |
| CN116250631B (en) * | 2023-02-10 | 2025-07-29 | 杭州百芮生物科技有限公司 | Embedding structure of probiotics and preparation method thereof |
| CN117918529A (en) * | 2023-12-28 | 2024-04-26 | 青岛蔚蓝生物集团有限公司 | Probiotic crystal ball containing lactobacillus plantarum and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110025638B (en) | Layer-by-layer self-assembled probiotic microcapsules of chitosan‐sodium carboxymethylcellulose and their preparation | |
| Rather et al. | Effect of double alginate microencapsulation on in vitro digestibility and thermal tolerance of Lactobacillus plantarum NCDC201 and L. casei NCDC297 | |
| Silva et al. | Symbiotic microencapsulation to enhance Lactobacillus acidophilus survival | |
| KR101918089B1 (en) | Method for coating lactic acid bacteria for increasing survival time of the Bacteria in intestine | |
| Islam et al. | Microencapsulation of live probiotic bacteria | |
| CN113558246B (en) | A kind of symbiotic bifidobacterium composite microcapsule and preparation method | |
| CN111588038A (en) | Seaweed enzyme probiotic microcapsule and preparation method thereof | |
| JP7688949B2 (en) | Method for preparing food-suppressing capsules containing multi-element nutritional microspheres and the resulting products | |
| CN104544086A (en) | Health food capable of improving intestinal flora and preparation method of health food | |
| TWM393167U (en) | Multi-coating macro-granule structure comprising probiotics | |
| CN109527563A (en) | A kind of synbiotics microcapsule and its preparation method and application | |
| CN107125767B (en) | Preparation method and application of composite microparticles of Bifidobacterium breve, Lactobacillus fermentum and Lactobacillus plantarum | |
| Marzorati et al. | A novel hypromellose capsule, with acid resistance properties, permits the targeted delivery of acid-sensitive products to the intestine | |
| CN115624180B (en) | Probiotics microcapsule containing osteopontin and preparation method thereof | |
| CN116270529B (en) | Human body-like nano microcapsule preparation for targeted treatment of helicobacter pylori and preparation method and application thereof | |
| US20070048295A1 (en) | Method for preparing alginate capsules | |
| WO2022266840A1 (en) | Probiotic microcapsule, and preparation method therefor and use thereof | |
| CN112890204A (en) | Microcapsule using grape seed extract as prebiotics and preparation method thereof | |
| CN110547468A (en) | Preparation method of probiotics microcapsule containing edible fungus oligosaccharide | |
| CN109007807A (en) | A kind of microcapsules fruit ferment powder and preparation method thereof | |
| CN116763755A (en) | A kind of probiotic microcapsule and preparation method thereof | |
| CN116178573A (en) | A kind of intestinal-targeted double-bacteria multinuclear gel particle and its preparation method | |
| TWI587863B (en) | A probiotic entrapping particle | |
| Gheisari et al. | Stability of Microencapsulated Lactobacillus Casei in Mango Fruit Juice and its Survival at Simulated Human Gastro-Intestinal Condition. | |
| CN114343186A (en) | Probiotics capsule for promoting enterokinesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4K | Annulment or lapse of a utility model due to non-payment of fees |